HOME >> BIOLOGY >> NEWS
CRESIB coordinates an international consortium to fight malaria caused by Plasmodium vivax

The CRESIB has today presented the research programme on malaria by Plasmodium vivax, a parasite causing over 70 million yearly cases of malaria in the world. This new programme will be developed in coordination with the leading international centres and researchers on P.vivax. The aim of this study is to contribute to a better understanding of malaria by P. vivax and to support and accelerate the development of new control tools, with a special focus in vaccines. This fact will promote the creation and development of a research line on P. vivax in CRESIB under the direction of Dr. Hernando A. del Portillo, one of the few specialists in molecular biology and vaccine development against this parasite. The number of CRESIB labs will be increased, with an enlargement and restoration of current facilities to meet the needs of the centre.

Malaria is an infectious disease which can be caused by four species of the Plasmodium parasite: P. falciparum, P. vivax, P. malariae and P. ovale. P. falciparum and P. vivax are the most prevalent, the first being more virulent and responsible of most of the severe morbidity and mortality. Nevertheless, during the last years, there has been a growing interest in malaria by P. vivax, which, as well as causing millions of malaria cases every year, it also generates a high social and economic cost for endemic countries. It is estimated that about 2,600 million people live in risk zones for P. vivax: central and south-America, Asia, Middle East and occidental Pacific. Clinical and pathogen presentation of P. vivax is not well understood. Despite the traditional belief that clinical malaria caused by this species of the parasite is mild, there are evidences suggesting that it can cause severe clinical patterns and even death of patients.

The paradox is that even though malaria by P. vivax has large global disease burden, this is a poorly studied disease,
'"/>

Contact: Marc de Semir
mdesemir@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
17-Jul-2007


Page: 1 2

Related biology news :

1. NYU biologists identify gene that coordinates two cellular processes
2. American buffalo slaughter fueled by international trade
3. 2 MSU professors spearhead international water project
4. Nature surrenders flowery secrets to international team
5. Fibers are center stage at international conference
6. Creation of an international industrial chair in life cycle assessment
7. The Institute of Ecosystem Studies to host an international conference on ecology and urban design
8. No sign that ethnic groups genes cause diabetes, international research team says
9. Research director to be honored at international congress
10. First international conference on self-healing materials
11. Case Western researcher, international team call for better global warming forecasting

Post Your Comments:
(Date:5/18/2013)... AGA Research Foundation is honored to announce the first ... Cancer, which will support Andrew D. Rhim, MD, from ... Pennsylvania, Philadelphia, as he furthers his research on the ... progression. , "The AGA Research Foundation is humbled to ... and AGA Legacy Society members," said Nicholas F. LaRusso, ...
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... FL (May 18, 2013) Research presented at ... managing digestive health through diet and lifestyle. ... plagued by reduced muscle strength, fatigue and poor ... when patients are in remission. A randomized, double ... that vitamin D supplementation corresponded to significant relief ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3
(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics ... recent annual meeting drew praise from community leaders from ... called the action “a huge step forward … a ... innovation.” , The Board of Stakeholders voted to approve ... at its 29 April meeting in Brussels, which was ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
Cached News: